Citation Impact
Citing Papers
Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
2006 Standout
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
2013 StandoutScience
Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites
2009 StandoutScience
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
2016
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
2013
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection
2012
Value of complete metabolic response by 18F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy
2007
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Gastric cancer
2016 Standout
Hypoxia-Inducible Factor-1-Dependent Repression of E-cadherin in von Hippel-Lindau Tumor Suppressor–Null Renal Cell Carcinoma Mediated by TCF3, ZFHX1A, and ZFHX1B
2006 StandoutNobel
Why do cancers have high aerobic glycolysis?
2004 Standout
A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer
2011
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Assessment of tumor response in malignant pleural mesothelioma
2007
Adjuvant and Neoadjuvant Therapy for Gastric Cancer
2005
Monitoring chemotherapy and radiotherapy of solid tumors
2006
The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening
2007
International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus
2014
[18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction?
2003
Differential Expression of the Epithelial-Mesenchymal Transition Regulators Snail, SIP1, and Twist in Gastric Cancer
2002
Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families
2001
Metabolic Tumor Width Parameters as Determined on PET/CT Predict Disease-free Survival and Treatment Response in Squamous Cell Carcinoma of the Esophagus
2008
Predictive Value of 18-Fluoro-Deoxy-Glucose-Positron Emission Tomography (18F-FDG-PET) in the Identification of Responders to Chemoradiation Therapy for the Treatment of Locally Advanced Esophageal Cancer
2006
The role of heat shock proteins in cancer
2015
Imaging in the era of molecular oncology
2008 StandoutNature
Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer1
2004
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
2007
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors
2008
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
2009
Epithelial-Mesenchymal Transitions
2004 Standout
Esophageal Cancer
2003 Standout
Complex networks orchestrate epithelial–mesenchymal transitions
2006 Standout
Cadherin and catenin alterations in human cancer
2002
Assessing responses to cancer therapy using molecular imaging
2006
Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements
1999
Epithelial–mesenchymal transitions in tumour progression
2002 Standout
Design considerations for tumour-targeted nanoparticles
2009 StandoutNobel
Perspectives in the treatment of gastric cancer
2005
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
2007 StandoutNature
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer
2002
Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer
2011
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Detection and chemoradiotherapeutic evaluation of advanced esophageal squamous cell carcinoma using gallium-67 SPET: a preliminary study
2002
Oesophageal carcinoma
2013 Standout
Hereditary Diffuse Gastric Cancer: Diagnosis and Management
2006
New approaches for imaging tumour responses to treatment
2008
Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer
2011
Emerging Biological Principles of Metastasis
2017 Standout
Differential Expression of E-Cadherin in Lobular and Ductal Neoplasms of the Breast and Its Biologic and Diagnostic Implications
2001
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
EMT: 2016
2016 Standout
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Intraoperative detection and removal of microscopic residual sarcoma using wide‐field imaging
2012 StandoutNobel
2‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma
2004
Autophagy and Aging
2011 Standout
18F-FDG PET/CT Role in Staging of Gastric Carcinomas
2015
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
2017
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
2004 Standout
Gastric cancer
2020 Standout
Neoadjuvant chemotherapy for advanced gastric cancer: A meta-analysis
2010
Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas
2008
Imaging in assessing lymph node status in gastric cancer
2009
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials
2008
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations
2008
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer
2006
The basics of epithelial-mesenchymal transition
2009 Standout
Unmet needs and challenges in gastric cancer: The way forward
2014
The Hallmarks of Aging
2013 Standout
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
Fibroblasts in cancer
2006 Standout
Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer
2004
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
2014 Standout
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
2007 StandoutNature
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
2016 StandoutNobel
Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast
2001
Modeling neurodevelopmental disorder-associated humanAGO1mutations inCaenorhabditis elegansArgonautealg-1
2024 StandoutNobel
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Convergence of Wnt, ß-Catenin, and Cadherin Pathways
2004 StandoutScience
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
2008
Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer
2005
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications
2019 Standout
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
2022
Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial
2003
New Technologies for Human Cancer Imaging
2008
Use of PET for monitoring cancer therapy and for predicting outcome.
2005
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Comparative Genomic Analysis of Esophageal Adenocarcinoma and Squamous Cell Carcinoma
2012
Positron Emission Tomography As an Imaging Biomarker
2006
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
2006
Positron-Emission Tomography and Assessment of Cancer Therapy
2006
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
2018 Standout
Evaluation of 18F‐2‐deoxy‐2‐fluoro‐d ‐glucose Positron Emission Tomography for Gastric Cancer
2004
Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer
2007
Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer
2003
Cancer Genome Landscapes
2013 StandoutScience
Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer
2005
Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
2006
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
2005
Efficient Enhancement of Electrochemiluminescence from Cadmium Sulfide Quantum Dots by Glucose Oxidase Mimicking Gold Nanoparticles for Highly Sensitive Assay of Methyltransferase Activity
2016
Global cancer statistics, 2012
2015 Standout
Tissue- and Organ-Selective Biodistribution of NIR Fluorescent Quantum Dots
2009 StandoutNobel
Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer
2009
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Monitoring cancer treatment with PET/CT: does it make a difference?
2007
Works of Katja Ott being referenced
Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy Response
2008
Diffuse Type Gastric and Lobular Breast Carcinoma in a Familial Gastric Cancer Patient with an E-Cadherin Germline Mutation
1999
Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET
2004
Prediction of Response and Prognosis by a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients
2012
Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study
2003
PET imaging with [11C]methyl-L-methionine for therapy monitoring in patients with rectal cancer
2002
FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings
2003
Association of angiogenic factors with prognosis in esophageal cancer
2015
European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer
2008
Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction
2007
DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer
2011
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
2007
Adenocarcinomas of Esophagogastric Junction: Multi–Detector Row CT to Evaluate Early Response to Neoadjuvant Chemotherapy
2006
Induction Chemotherapy in Barrett Cancer
2007
Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer
2017
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy
2003
Individualized neoadjuvant treatment strategy in adenocarcinoma of the esophago-gastric junction (AEG): Interim report on the MUNICON trial
2004
Combined GADD45A and Thymidine Phosphorylase Expression Levels Predict Response and Survival of Neoadjuvant-Treated Gastric Cancer Patients
2005
Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.
2003
Individualized neoadjuvant treatment strategy in adenocarcinoma of the esophago-gastric junction (AEG): Interim report on the MUNICON trial
2004
Individualized indication for neoadjuvant treatment based on metabolic response Assessed by 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in adenocarcinoma of the esophago-gastric junction (AEG)
2005
Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954
2010
Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial
2003
Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein–Barr virus infection and high‐ and low‐microsatellite instability
2019
Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction.
2005
Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study
2008
Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging
2001
Prognostic Significance of Free Peritoneal Tumor Cells in the Peritoneal Cavity Before and After Neoadjuvant Chemotherapy in Patients with Gastric Carcinoma Undergoing Potentially Curative Resection
2010
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
2006
Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma.
2000